HomeHealthNAFDAC alerts public against use of weight loss pill

NAFDAC alerts public against use of weight loss pill

Date:

Related stories

Nigeria Health Watch’s Kaduna policy dialogue promotes sustainable PHC financing

– Benjamin Joseph Nigeria Health Watch’s policy dialogue, themed “Advancing...

Garki Hospital concession renewal praised for improving service delivery

The renewal of Garki Hospital’s concession to Nisa Medical...

Nigeria faces HIV drug shortages – WHO

The World Health Organization (WHO) has warned that Nigeria...

SFH launches SWIFT project to combat maternal mortality

The Society for Family Health (SFH) has launched the...

NAFDAC seeks death penalty for fake drug peddlers

The National Agency for Food and Drug Administration and...
spot_img

The National Agency for Food and Drugs Administration and Control (NAFDAC) has cautioned Nigerians against the use of the drug  — Weight Rapid Loss Capsule.

The caution is contained in an alert with No. 049/2022, signed by NAFDAC’s Director-General, Prof. Mojisola Adeyeye, issued to the News Agency of Nigeria (NAN) on Sunday in Abuja.

Adeyeye stated that the drug has been found to have potential to cause cancer.

The NAFDAC boss added that result of laboratory analysis showed that the drug, manufactured by Ingi Oman, contain banned substance “phenolphthalein”, which the U.S. Food and Drug Administration recognised as unsafe.

She added that the capsule, being marketed as “the most effective weight loss supplement” and sold through social media platforms like Instagram, also contain microbial growth above permissible limits.

She stated that “phenolphthalein has been found to be toxic to genes, as it can cause damage or mutations in the DNA. Studies have also shown its potential carcinogenic risks.

“NAFDAC implores consumers to stop the purchase and use of the product.

“Members of the public in possession of the product should discontinue use or sale, and submit stock to the nearest NAFDAC office.”

Adeyeye encouraged healthcare professionals and consumers to report any adverse effect experienced with the use of the product to the nearest NAFDAC office.

Consumers are also advised to report adverse effect via p[email protected] or E-reporting platforms available at www.nafdac.gov.ng.

The director-general urged the public to also report any incident concerning the use of the drug via the Med-safety application, which can be downloaded on android and IOS stores.

NAN

Subscribe

Latest stories

LEAVE A REPLY

Please enter your comment!
Please enter your name here